Zealand Pharma A/S
CSE:ZEAL

Watchlist Manager
Zealand Pharma A/S Logo
Zealand Pharma A/S
CSE:ZEAL
Watchlist
Price: 469 DKK 1.6% Market Closed
Market Cap: 33.3B DKK

Wall Street
Price Targets

ZEAL Price Targets Summary
Zealand Pharma A/S

Wall Street analysts forecast ZEAL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ZEAL is 980.22 DKK with a low forecast of 757.5 DKK and a high forecast of 1 207.5 DKK.

Lowest
Price Target
757.5 DKK
62% Upside
Average
Price Target
980.22 DKK
109% Upside
Highest
Price Target
1 207.5 DKK
157% Upside
Zealand Pharma A/S Competitors:
Price Targets
MNKD
MannKind Corp
112% Upside
BIOPOR
Bioporto A/S
161% Upside
LTRN
Lantern Pharma Inc.
478% Upside
CUV
Clinuvel Pharmaceuticals Ltd
128% Upside
300406
Beijing Strong Biotechnologies Inc
69% Upside
NTRA
Natera Inc
32% Upside
206650
EuBiologics Co Ltd
25% Upside
ELUT
Elutia Inc
315% Upside

Revenue
Forecast

Revenue Estimate
Zealand Pharma A/S

For the last 8 years the compound annual growth rate for Zealand Pharma A/S's revenue is -15%. The projected CAGR for the next 3 years is 204%.

-15%
Past Growth
204%
Estimated Growth
Estimates Accuracy
-23%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Zealand Pharma A/S

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-7%
Average Miss

Net Income
Forecast

Net Income Estimate
Zealand Pharma A/S

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-33%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ZEAL's stock price target?
Price Target
980.22 DKK

According to Wall Street analysts, the average 1-year price target for ZEAL is 980.22 DKK with a low forecast of 757.5 DKK and a high forecast of 1 207.5 DKK.

What is Zealand Pharma A/S's Revenue forecast?
Projected CAGR
204%

For the last 8 years the compound annual growth rate for Zealand Pharma A/S's revenue is -15%. The projected CAGR for the next 3 years is 204%.

Back to Top